Brief: Arctic Bioscience Announces top-line results from the phase 2b HeROPA study

Arctic Bioscience AS

14/10/2024 18:12

Oct 14 (Reuters) - Arctic Bioscience AS  ABSA.OL :
    * ARCTIC BIOSCIENCE AS - PLACEBO RATE WAS UNEXPECTEDLY HIGH,
PREVENTING ACHIEVEMENT OF PRIMARY END-POINT
    * ARCTIC BIOSCIENCE AS  - ALL PATIENTS HAVE PASSED 6 MONTHS
OF
TREATMENT IN HEROPA PHASE 2B CLINICAL STUDY, WHICH COMPARED
HRO350 TO PLACEBO
    * ARCTIC BIOSCIENCE AS: WILL ALSO PERFORM A FULL STRATEGIC
AND
ORGANIZATIONAL ASSESSMENT TO SECURE A SUSTAINABLE FINANCIAL
PLATFORM

Source text for Eikon:  ID:nWkr72Ts3g 
Further company coverage:  ABSA.OL 

 ((Reuters.Briefs@thomsonreuters.com;))